Pediatric Dermatology

Verrica’s VP-102 is the first FDA-approved treatment for molluscum lesions.

Researchers conducted a systematic review and meta-analysis of probiotic treatment efficacy in children with atopic dermatitis.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Adelaide Hebert, MD, reviewed ichthyosis, epidermolysis bullosa, molluscum contagiosum, and more at the 2023 Fall Clinical Dermatology Conference for PAs and NPs.

Benjamin encouraged attendees at SCALE 2023 to think beyond just topicals for pediatric acne.

Dermatology advanced practice providers work alongside physicians to improve patient care and access.

Novan’s expected PDUFA date is January 5, 2024.

Treatment is not mandatory and, in fact, clinicians are still without an FDA-approved treatment option, but parents often insist on some sort of action.

“So much new in the world of pediatric dermatology—new and novel treatments for atopic dermatitis, hemangiomas, childhood blistering diseases, warts. We are practicing during the Golden Age of dermatology,” Swanson says.

Potential FDA approval is expected in the first quarter of 2024.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

A variety of topicals and biologics are now available to treat children affected by this challenging condition.

Shanna Miranti, MPAS, PA-C, shares highlights from her first session at the 2022 SDPA Conference in Miami, Florida.

At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients

Congenital malalignment syndrome is a nail disorder caused by the lateral rotation of the nail matrix.

Management differs from adults and requires a meticulous examination to rule out underlying diseases.

A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.

It is crucial to better understand, diagnose, and manage this skin condition associated with significant quality-of-life impairment.

The effect of acne is more than skin deep.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

An expert offers considerations and developmentally appropriate interventions to promote high-quality, patient-centered pediatric infusion care.

Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.

At the SPD 2022 47th Annual Meeting, we chat with Albert Yan, MD, of Children's Hospital of Philadelphia on the latest trends in technology for pediatric dermatologists.

At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.

At the SPD 2022 47th Annual Meeting, a recap of don’t-miss sessions for Sunday, July 10.